NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community. The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Clinical Roundup

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Investigator-initiated EFTISARC-NEO phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus Keytruda (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.

May 30, 2025

Vol.51 No.21

Regulatory News

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

On May 21, staff members of NCI’s dissolved Office of Communications and Public Liaison and friends gathered at the house of Peter Garrett and Ken Crerar.

May 23, 2025

Vol.51 No.20

NCI strategy for evaluating MCED assays may bypass cancer clinical trials groups

YOU MAY BE INTERESTED IN

Surviving cancer is often not a patient’s most challenging battle

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

KU Cancer Center breaks ground for new complex

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo

Renew today!

Subscriber content

Never miss an issue!

Login